Article info

Extended report
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Authors

  1. Correspondence to Dr Ronald F van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska University Hospital, D1:00, 17176, Stockholm, Sweden; ronald.van.vollenhoven{at}ki.se
View Full Text

Citation

van Vollenhoven RF, Emery P, Bingham CO, et al
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Publication history

  • Accepted September 11, 2012
  • First published November 7, 2012.
Online issue publication 
August 06, 2013

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.